Biosion
Nanjing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel antibody therapeutics, including bispecifics, for cancer and autoimmune diseases using proprietary discovery platforms.
OncologyImmunology
Technology Platform
Proprietary H³ antibody discovery platform and BEAT bispecific antibody platform for generating fully human, high-affinity therapeutic candidates.
Opportunities
Potential for lucrative partnership deals or acquisition based on positive clinical data from its bispecific antibody oncology programs.
Risk Factors
Clinical failure of lead assets could significantly impact valuation and the ability to raise capital for further development.
Competitive Landscape
Operates in the highly competitive global antibody therapeutics space, requiring differentiation through novel mechanisms and strong clinical data.